Diazoxide Powder
NDC Package 45562-1740-0

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Diazoxide powders is a medication used to treat very low blood sugar (hypoglycemia). This formulation utilizes a powder delivery system. Marketed by Lundbeck Pharmaceuticals Italy S.p.a., this product is identified by NDC 45562-1740.

Identification & Billing

NDC Package Code
45562-1740-0
Package Description
10 kg in 1 DRUM
Product Code
45562-1740
11-Digit Billing Format
45562174000

Clinical Specifications

Proprietary Name
Diazoxide
Non-Proprietary Name
Diazoxide
Substance Name
Diazoxide
Dosage Form
Powder - An intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use.
Active Ingredient(s)
DIAZOXIDE 1 kg/kg
Usage Information
This medication is used to treat very low blood sugar (hypoglycemia). Certain conditions (such as tumor on the pancreas, cancer, leucine sensitivity) can cause the release of too much insulin. Insulin is a natural substance that lowers blood sugar. This drug works by preventing insulin release from the pancreas, helping to return the blood sugar to normal levels. Diazoxide is a thiazide drug, but has no diuretic ("water pill") effects like other thiazides. Diazoxide should not be used to treat low blood sugar from poor nutrition/diet (functional hypoglycemia).

Regulatory & Marketing

Labeler Name
Lundbeck Pharmaceuticals Italy S.p.a.
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
02-19-2001
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 45562-1740-0 identifies a specific commercial package of 10 kg in 1 drum of Diazoxide (UNFINISHED drug), drug for further processing labeled by Lundbeck Pharmaceuticals Italy S.p.a.. This powder is formulated for use and contains diazoxide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lundbeck Pharmaceuticals Italy S.p.a. on February 19, 2001. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat very low blood sugar (hypoglycemia). Certain conditions (such as tumor on the pancreas, cancer, leucine sensitivity) can cause the release of too much insulin. Insulin is a natural substance that lowers blood sugar. This drug works by preventing insulin release from the pancreas, helping to return the blood sugar to normal levels. Diazoxide is a thiazide drug, but has no diuretic ("water pill") effects like other thiazides. Diazoxide should not be used to treat low blood sugar from poor nutrition/diet (functional hypoglycemia).

How is this Lundbeck Pharmaceuticals Italy S.p.a. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 45562174000. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
45562-1740-0
11-Digit CMS (5-4-2)
45562-1740-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.